Joakin O Mori
Overview
Explore the profile of Joakin O Mori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
18
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mori J, Platz E, Lu J, Brame A, Han M, Joshu C, et al.
Front Med (Lausanne)
. 2024 Jun;
11:1390769.
PMID: 38895181
Background: Telomeres are located at chromosomal termini and function to maintain genomic integrity. Telomere dysfunction is a well-recognized contributor to aging and age-related diseases, such as prostate cancer. Since telomere...
2.
Mori J, Elhussin I, Brennen W, Graham M, Lotan T, Yates C, et al.
Nat Rev Urol
. 2023 Nov;
21(5):258-273.
PMID: 37907729
The stromal component of the tumour microenvironment in primary and metastatic prostate cancer can influence and promote disease progression. Within the prostatic stroma, fibroblasts are one of the most prevalent...
3.
Mori J, Keegan J, Flynn R, Heaphy C
J Clin Pathol
. 2023 Oct;
77(2):82-86.
PMID: 37890990
Telomere maintenance and elongation allows cells to gain replicative immortality and evade cellular senescence during cancer development. While most cancers use telomerase to maintain telomere lengths, a subset of cancers...
4.
Mori J, White J, Elhussin I, Duduyemi B, Karanam B, Yates C, et al.
Front Oncol
. 2022 Aug;
12:928357.
PMID: 36033462
Prostate cancer (PCa) disproportionately affects African American (AA) men, yet present biomarkers do not address the observed racial disparity. The objective of this study was to identify biomarkers with potential...
5.
Mori J, Shafran J, Stojanova M, Katz M, Gignac G, Wisco J, et al.
Prostate
. 2022 Apr;
82(10):1005-1015.
PMID: 35403746
In patients with prostate cancer, the duration of remission after treatment with androgen deprivation therapies (ADTs) varies dramatically. Clinical experience has demonstrated difficulties in predicting individual risk for progression due...